Tirzepatide vs Semaglutide: What the Head-to-Head Trials Show

Title card: tirzepatide versus semaglutide head-to-head trials

Tirzepatide (sold as Mounjaro and Zepbound) and semaglutide (Ozempic, Wegovy) are the two best-known weekly injections for weight and blood sugar. People ask the same question about them constantly: which one works better? Unlike many comparisons online, this one has real head-to-head trial data. This post walks through what those trials found, where the evidence is thinner, and what the numbers do not tell you.

The two drugs in one paragraph

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GLP-1 receptor and the GIP receptor, which is why it is often called a “dual agonist.” Both reduce appetite, slow stomach emptying and improve insulin signaling. Whether the extra GIP activity explains tirzepatide’s results is still debated, but the clinical differences between the drugs are now documented in randomized trials.

SURMOUNT-5: the key obesity trial

SURMOUNT-5 randomized adults with obesity (without type 2 diabetes) to tirzepatide or semaglutide, each at the maximum tolerated dose, and followed them for 72 weeks. Tirzepatide doses were 10 mg or 15 mg and semaglutide doses were 1.7 mg or 2.4 mg. According to the American College of Cardiology summary of the trial, average body weight fell about 20.2% with tirzepatide and 13.7% with semaglutide, a gap of about 6.5 percentage points. In kilograms, that was roughly 22.8 kg versus 15.0 kg.

Bar chart of SURMOUNT-5 weight loss, tirzepatide 20.2 percent versus semaglutide 13.7 percent

The threshold results tell the same story. Reported figures for the share of participants losing at least 10%, 15%, 20% and 25% of body weight were 81.6%, 64.6%, 48.4% and 31.6% on tirzepatide, compared with 60.5%, 40.1%, 27.3% and 16.1% on semaglutide. Waist circumference fell by about 18.4 cm versus 13.0 cm. Note that different outlets have printed slightly different headline percentages for this trial, so use the published paper if you need exact values.

SURPASS-2: the diabetes comparison

In people with type 2 diabetes the picture is similar, though the gaps are smaller. The SURPASS-2 trial randomized about 1,880 adults on metformin to tirzepatide (5, 10 or 15 mg) or semaglutide 1 mg for 40 weeks. HbA1c fell by roughly 1.9% with semaglutide and by about 2.0% to 2.5% with tirzepatide, depending on dose and how the analysis was done. Weight loss was larger with every tirzepatide dose, with differences versus semaglutide of about 1.9, 3.6 and 5.5 kg. One caveat: this trial compared tirzepatide with the 1 mg semaglutide dose, not the higher 2.4 mg dose used for weight management.

Tolerability: not a clear loss for either

Both drugs cause nausea, vomiting, diarrhea and constipation, especially during dose escalation. In SURMOUNT-5, stopping treatment because of gastrointestinal side effects was reported in about 2.7% of people on tirzepatide and 5.6% on semaglutide. That is one trial at maximum tolerated doses, and the design let participants settle at a dose they could handle, so it does not mean tirzepatide is gentler for everyone. For a fuller look at adverse effects, see our post on tirzepatide side effects and what the label shows.

Heart outcomes: the evidence is mixed

Weight loss is not the only thing people care about. Semaglutide has its own large cardiovascular outcome trial results, and tirzepatide’s dedicated outcome data are still catching up. In the meantime, observational studies have compared the two using insurance and health-record data, and they do not agree. Several large analyses in people with diabetes found only small differences in heart outcomes. Some cohorts of adults with obesity favored tirzepatide, while a company-sponsored analysis in people with established cardiovascular disease reported fewer events with semaglutide.

These are retrospective studies. Patients who get one drug rather than the other differ in many ways that statistics cannot fully correct, and several of these results come from conference abstracts or press releases rather than full papers. Treat them as hypotheses, not verdicts.

What the trials do not tell you

  • Averages hide a wide range. Some people lose far more than 20% and some lose far less. Responses to both drugs vary widely, and the trials report group means.
  • Trial participants are selected. People in trials are monitored closely and follow diet and activity counseling. Real-world results are often smaller.
  • Sex and body size matter. In SURMOUNT-5, men lost about six percentage points less than women on both drugs.
  • Weight regain after stopping is common. Both drugs work while you take them. Long-term results depend on continued treatment or other changes.
  • Cost and access can decide the question. Coverage, supply and price often matter more to the person than a few percentage points of weight loss.

Why might tirzepatide work better?

Nobody can say for certain. The leading explanation is the dual mechanism: GIP signaling may add to the appetite and metabolic effects of GLP-1 activation, and there is some evidence it may help reduce nausea at higher doses. But the trials were not designed to isolate the mechanism, and the doses are not directly equivalent either. Tirzepatide is titrated to as much as 15 mg weekly, while semaglutide for weight management tops out at 2.4 mg. Part of the gap may reflect how far each drug can be pushed, and part may reflect biology. Researchers are still sorting this out.

How treatment starts: slow titration for both

Both medicines are started at low doses and raised gradually, usually every four weeks, to give the digestive system time to adjust. That is why trial results at 72 weeks reflect months of dose escalation rather than a fast start, and why the early weeks often bring the most nausea. Skipping steps or taking leftover doses on your own is a common cause of misery, and it is one more reason these drugs are meant to be supervised by a prescriber. Maintenance doses are individualized, and a lower dose that someone can tolerate and stay on may serve them better than a higher dose they abandon.

Who was left out of these trials?

Head-to-head trials enroll people who meet strict criteria, and they usually exclude those with certain conditions, such as a history of pancreatitis or specific thyroid cancers, or those who are pregnant. Participants also tend to be motivated and closely followed. If you have a condition outside the trial population, the results may not apply, and the person to ask is your own clinician, who knows your history. The same applies to older adults, teenagers, and people with significant kidney or liver disease, who were often studied separately or not at all in these particular comparisons.

A note on compounded and “research” versions

Both drugs have been widely copied and sold online. Trial results apply to the approved products at the studied doses, made under pharmaceutical quality controls. They do not transfer to unregulated products whose contents and strength may differ from the label. If a seller quotes trial numbers to market a research-grade vial, that is a mismatch worth questioning.

Bottom line

In head-to-head trials, tirzepatide produced more weight loss than semaglutide in people with obesity, and more weight loss and greater HbA1c reduction in people with type 2 diabetes. The difference is real but moderate, individual results vary, and the long-term heart and safety comparisons are still being worked out. The “better” drug for any one person depends on their health history, side effects, cost and goals, which is a conversation for a clinician. Questions or experiences to share? The forum is open.

This article is for educational purposes only and is not medical advice. Trial figures are drawn from published summaries and may differ slightly from the original papers. Talk to a qualified clinician about prescription treatments.

Leave a Reply